Cytosorbents Corp. (CTSO) — 分析摘要
Cytosorbents Corp.（CTSO）的市值为22.62百万美元，最近一年的营收同比增长了+4.1%。净利润率为-22.1%。当前市盈率为-1.9倍。
核心要点
- 营收同比变化+4.1%
- 净利润率-22.1%
- 市盈率-1.9倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比，CTSO的营收增长为+4.1%，市盈率为-1.9倍。
Cytosorbents Corp. (CTSO)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
D/E 为 7.7x — 杠杆极高
营业利润率为 -37.4% — 经营亏损显著
净利率为 -31.9% — 亏损显著
净利润较上一期下降 44.5%。
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
129
总部
PRINCETON, NJ
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。